Malaria Treatments

Dafra Pharma International has always been at the forefront of the Artemisinin based Combination Therapies (ACT's¹) for the treatment of malaria.

Since April 2001, the World Health Organisation (WHO) has recommended the use of artemisinin-based combination therapies (ACT's) for the treatment of Plasmodium falciparum malaria or Uncomplicated malaria.

ACT's ensure the highest cure rates and have the potential to reduce the spread of drug resistance. They are now generally considered as the best current treatment for uncomplicated falciparum malaria.

As each individual country aims to offer antimalarials that are the most effective in their respective country, African countries have adopted different ACT's in their national antimalarial treatment policies.

The main determinant of policy change is the therapeutic efficacy and the consequent effectiveness of the antimalarial in use. Other important determinants include: changing patterns of malaria-associated morbidity and mortality; consumer and provider dissatisfaction with the current policy; and the availability of new products, strategies and approaches².

The following ACT's are currently recommended by the WHO

  • artemether + lumefantrine
  • artesunate + amodiaquine
  • artesunate + mefloquine
  • artesunate + sulfadoxine–pyrimethamine³

Responding to the different needs of the African countries, Dafra Pharma International can offer a wide range of antimalarial medication:
  • Artemisinin based Combination Therapies (ACT’s) for Uncomplicated malaria in a variety of strengths and presentations.
    • Artesunate + Sulfadoxine/Pyrimethamine (co-blister tablets)
    • Artesunate + Sulfametoxypyrazine/Pyrimethamine (co-blister tablets)
  • Mono compounds based on artemisinin derivatives for Severe malaria and/or Emergency treatment
    • Artemether Suppogel
    • Artemether for IntraMuscular Use
Since the beginning Dafra Pharma International has paid special attention to the most vulnerable group, namely children.


Nowadays Dafra Pharma International is specialised in a wide range of paediatric presentations:
  • Artemisinin based mono- and combination therapies (ACT’s) in Paediatric Presentations for the most vulnerable group, namely children
    • Artemether + Lumefantrine (FDC powder for oral suspension/syrup)
    • Artesunate + Sulfadoxine/Pyrimethamine (co-blister tablets)
    • Artesunate + Sulfametoxypyrazine/Pyrimethamine (Co-blister tablets)
    • Artemether Suppogel
    • Artemether for IntraMuscular Use
Contact: sales@dafra.be


Other new anti-malaria treatments based on Artemisinin derivatives are continually being researched and developed

Contact: research@dafra.be
TOP




¹ ACT= Artemisinin-based combination therapy = A combination of artemisinin or one of its derivatives with a partner drug which is an antimalarial or antimalarials of a different class.
² http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf
³ A similar medicine with tablets containing 500 mg of sulfalene and 25 mg of pyrimethamine is considered to be equivalent to sulfadoxine-pyrimethamine.






Branded Generics

Since 2006/2007 Dafra Pharma International has opened its unique African distribution network for the marketing and promotion of non-malaria treatments. It concerns first class medications that have gone off patent :

  • Amoxicilline / Clavulanic acid
    A broad spectrum antibiotics of the beta-lactamase
  • Ibuprofen
    Analgetic and antipyretic of the family of the non-steroidal anti-inflammatory products
  • Ciprofloxacine
    Quinolone antibiotic of the second generation
  • Paracetamol
  • Ferric Ammonium Citrate

Contact: nbd@dafra.be
TOP






Consumer Health Products

Since 2006/2007 Dafra Pharma International has opened its unique African distribution network for the marketing and promotion of consumer health products.

Anaeban®
Food supplement based on probiotica.
  • forms & presentations:
    • Box with 24 capsules.
  • Indication:
    • Promotes the advancement and maintenance of a balanced flora. Use is also possible during treatment with antibiotics or when travelling.
DafraVit®
Vitamin supplement for children from 2 years on.
  • forms & presentations:
    • Box with 5 sachets (9mg) to dissolve.
  • indication:
    • DafraVit® is a multi-vitamin and mineral formulation to support optimal health and vitality.
Fortaline®
Omega-3 rich fish oil supplements.
  • forms & presentations:
    • 20 Soft gel capsules.
    • Oral suspension 100ml.
  • indication:
    • Omega-3
    • Increases birth weight.
    • Decreases the risk of premature birth.
    • Helps brain development.
    • Improves visual development.
    • Protects the skin from aging.
    • Supports the immune system.
    • Supports your health and blood pressure.
    • Improves your metabolism.
    • Helps keeping your joints flexible.
    • Promotes your emotional well- being and positive mental outlook.
Amifer®
Iron Syrup & capsules
  • forms & presentations:
    • Oral suspension 200 ml.
  • indication:
    • Amifer® syrup is used to treat and prevent iron and folic acid deficiency.
  Pico®
Mosquito and Midge repellent.
  • forms & presentations:
    • Roll-on (20% DEET) - 60 ml
    • Stick (10% DEET) - 20 ml
    • Spray (50% DEET) - 50 ml
  • indication:
    • Repellent and mosquito protection.
Sania®
Waterfree, disinfecting and refreshing hand-sanitizer.
  • forms & presentations:
    • Gel - 45ml
  • indication:
    • Provides absolute hygiene while purifying your hands from bacteria.
Kinazol®
Shampoo against dandruff.
  • forms & presentations:
    • shampoo 60 or 100 ml.
  • indication:
    • Kinazol® stops and prevents dandruff.
TOP